Novelty in the treatment of patients with uterine myoma

Shamugia N.M.

Department of Reproductive Medicine and Surgery, Faculty of Postgraduate Professional Education, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

Adamyan L.V.

SPIN RSCI: 9836-2713
Scopus AuthorID: 7006372422
ResearcherID: Q-1722-2018
ORCID: 0000-0002-3253-4512

Sonova M.M.

Kafedra reproduktivnoĭ meditsiny i khirurgii fakul'teta poslediplomnogo obrazovaniia Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Arslanyan K.N.

Loginova O.N.

Kafedra reproduktivnoĭ meditsiny i khirurgii fakul'teta poslediplomnogo obrazovaniia Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Laskevich A.V.

Novelty in the treatment of patients with uterine myoma

Authors:

Shamugia N.M., Adamyan L.V., Sonova M.M., Arslanyan K.N., Loginova O.N., Laskevich A.V.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2015;15(3): 76‑80

DOI: 10.17116/rosakush201515376-80

Downloaded: 11

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Shamugia NM, Adamyan LV, Sonova MM, Arslanyan KN, Loginova ON, Laskevich AV. Novelty in the treatment of patients with uterine myoma. Russian Bulletin of Obstetrician-Gynecologist. 2015;15(3):76‑80. (In Russ.)
https://doi.org/10.17116/rosakush201515376-80

Подписка 2025-2 (Russian Bulletin of Obstetrician-Gynecologist)

Close metadata

Recommended articles:

Experience of combined treatment of patients with infertility operated for external genital endometriosis. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):77-81

Controversial issues of adjuvant therapy after myomectomy. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):101-107

Structural and biochemical features of menstrual discharge in patients with uterine fibroids. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):85-90

Comparative analysis of the effectiveness of therapy for endometrial hyperplasia in women of reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):75-83

Benign breast diseases in the focus of proliferative pathology of the reproductive system. Russian Journal of Human Reproduction. 2024;(3):33-42

A clinical case of parasitic fibroids on the mesentery of the sigmoid colon. Russian Journal of Human Reproduction. 2024;(3):105-110

The place of GnRH antagonists in modern ART programs: the possibilities of using of new drug of ganirelix. Russian Journal of Human Reproduction. 2024;(4):38-50

Tolerability of multiphasic and monophasic combined hormonal contraceptives patients with uterine fibroids. Russian Journal of Human Reproduction. 2024;(4):78-89

Heterogeneity of the molecular phenotype with uterine fibroids. Message I. Russian Journal of Human Reproduction. 2024;(4):121-130

Heterogeneity of the molecular phenotype with uterine fibroids. Message II. Russian Journal of Human Reproduction. 2024;(5):15-24

Objective — to optimize management tactics using the selective progesterone receptor modulator ulipristal acetate as an agent for preoperative preparation for patients with uterine myoma. Subject and methods. Seventy women aged 35 to 45 years with symptoms of uterine myoma were examined. Thirty patients were treated with ulipristal acetate in a daily dose of 5 mg for 13 weeks. Thirty women received the gonadotropin-releasing hormone agonist buserelin acetate 3.75 mg intramuscularly thrice every 28 days. The data of 10 patients who had preferred surgery without hormonal pretreatment were used as a control group. All had undergone myomectomy or hysterectomy. Results. Compared to gonadotropin-releasing hormone agonist injections, ulipristal acetate promoted arrest of uterine bleeding, correction of anemia, and a decrease in myoma sizes. Conclusion. Ulipristal acetate in a daily dose of 5 mg is more effective than once monthly buserelin acetate injections as an agent for preoperative preparation in patients with symptoms of uterine myoma. The authors declare no conflicts of interest.

Keywords:

uterine myoma

ulipristal acetate

gonadotropin-releasing hormone agonists

Authors:

Shamugia N.M.

Adamyan L.V.

SPIN RSCI: 9836-2713
Scopus AuthorID: 7006372422
ResearcherID: Q-1722-2018
ORCID: 0000-0002-3253-4512

Sonova M.M.

Kafedra reproduktivnoĭ meditsiny i khirurgii fakul'teta poslediplomnogo obrazovaniia Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Arslanyan K.N.

Loginova O.N.

Kafedra reproduktivnoĭ meditsiny i khirurgii fakul'teta poslediplomnogo obrazovaniia Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Laskevich A.V.

List of references:

. Duhan N. Current and emerging treatments for uterine myoma — an update. International Journal of Women’s Health. 2011;3:231-241.
Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Terrill P. Ulipristal acetate versus placebo for fibroid treatment before surgery. (PEARL I). N Engl J Med .2012;366:5:409-420.
Donnez J, Tomaszewski J, Vázquez FF Baró, Nouri K, Selvaggi L, Sodowski K, Bestel E, Terrill P, Osterloh I. Ulipristal acetate versus leuprolide acetate for uterine fibroids. (PEARL II). N Engl J Med. 2012;366:5:421-432.
Cardozo ER, Clarc AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. Treestimated annual cost of uterine leiomyomatain the United States. Am J Obstet Gynecol. 2012;206:3.
Adamyan L.V., Kulakov V.I. Endoskopia v ginekologii [Endoscopy in gynecology. Moscow: Medicina Publ 2000;79-93. (In Russ.).
Guidelines to the diagnosis and treatment of uterine leiomyoma. Moscow: MEDpress-inphorm Publ 2004;400. (In Russ.).
Horak P, Mara M, Dundr P, Kubinova K, Kuzel D, Hudecek R, Chmel R. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids In vivo. International Journal of Endocrinology. 2012;2012; Article ID 436174, 6.
Carpenter ТТ, Walker WJ. Pregnancy following uterine artery embolisation for symptomatic fibroids: a series of 26 completed pregnancies. BJOG. 2005;112:321-325.
Chabbert-Buffet N, Meduri G, Bouchard Ph, Spitz IS. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Human Reprod Update. 2005;11:3:293-307.
Sinclair DC, Mastroyannis A, Taylor HS. Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-beta3. Clin Endocrinol Metabol. 2011;96:412-421.
Agarwal SK. Comparative effects of GnRH agonist therapy. Review of clinical studies and their implications. J Reprod Med. 1998;43:293-298.
McCarthy-Keith DM, Armstrong AY. Innovations in uterine fibroid therapy. Therapy. 2011;8:2:189-200.
Stewart EA, Rabinovich J, Tempany CM. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril. 2006;85:22-29.
Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007;87:4:725-736.
Clinical Guideline 44. Heavy menstrual bleeding. National Collaborating Centre for Women’s and Children’s Health http://www.nice.org.uk.
Al-Mahrizi S, Tulandi T. Treatment of uterine fibroids for abnormal uterine bleeding: myomectomy and uterine artery embolization. Best Pract Res Clin Obstet Gynaecol. 2007;21:6:995-1005.
Maruo T, Ohara N, Yoshida S. Translational research with pro-gesterone receptor modulator motivated by the use of levonorgestrel releasing intrauterine system. Contraception. 2010;82:5:435-441.
Sienera P, Arisio R, Decko A, Farina C, Grana F. Laparoscopic myomectomy: indications, surgical technique and complications. Human Reprod. 1997;12:1927-1930.
Spies JB, Cooper JM, Worthington-Kirsch R. Outcome of uterine embolization and hysterectomy for leiomyomas: results of a multicentre study. Am J Obstet Gynecol. 2004;191:22-31.
Hindley J, Gedroyc WMW, Regan L. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. Am J Roentgenol. 2004;183.

Close metadata